- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03528863
Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers
Being Present 2.0: Web-Based Mindfulness Meditation for Gastrointestinal Cancer Patients and Caregivers
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVES:
I. To determine the feasibility and acceptability of an 8-week web-based mindfulness meditation program with live webinars among patients with a metastatic gastrointestinal (GI) cancer receiving chemotherapy and their caregivers.
SECONDARY OBJECTIVES:
I. Estimate the efficacy of an 8-week web-based mindfulness meditation program with live webinars among patients with a metastatic GI cancer receiving chemotherapy and their caregivers.
OUTLINE:
Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
After completion of study, participants are followed up at 8 weeks.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
San Francisco, California, Yhdysvallat, 94115
- University of California, San Francisco
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- ELIGIBLE PATIENTS: Carry a diagnosis of a metastatic GI cancer
- ELIGIBLE PATIENTS: Anticipate receiving chemotherapy for at least 12 weeks total from the time of recruitment
- ELIGIBLE PATIENTS: Have an estimated life expectancy of at least 6 months, assessed by principal investigator or treating investigator
- ELIGIBLE PATIENTS: Have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2
- ELIGIBLE PATIENTS: Be able to speak and read English
- ELIGIBLE PATIENTS: Be able to navigate websites, fill out forms on the web, communicate by email, and have regular access to the internet (assessed by participant self-report)
- ELIGIBLE PATIENTS: Have daily access to a mobile phone capable of receiving text messages, as determined by a study investigator
- ELIGIBLE PATIENTS: Be able to provide informed consent
- ELIGIBLE CAREGIVERS: Be a spouse/partner, other family member, or a close friend of a patient who consented to participate in the Being Present 2.0 study
- ELIGIBLE CAREGIVERS: Be able to speak and read English
- ELIGIBLE CAREGIVERS: Be able to navigate websites, fill out forms on the web, communicate by email, and have regular access to the internet (assessed by participant self-report)
- ELIGIBLE CAREGIVERS: Have access to a mobile phone capable of receiving text messages, as determined by a study investigator
- ELIGIBLE CAREGIVERS: Be able to provide informed consent
Exclusion Criteria:
- Have a current meditation practice (> 2 episodes or > 1 hour total, weekly)
- Be currently enrolled in a stress reduction program
- Have extensive hearing loss such that ability to participate in the study would be impaired
- Have participated in the original Being Present pilot study (BP1)
- Be caregivers of patients who decline Being Present 2.0 (BP2) study participation
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Supportive Care (web-based mindfulness meditation)
Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks.
Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
|
Apututkimukset
Receive web-based mindfulness meditation
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility as assessed by evaluating recruitment rate
Aikaikkuna: At end of enrollment (Up to 1 year)
|
Number of participants approached who consent to participate
|
At end of enrollment (Up to 1 year)
|
|
Feasibility as assessed by evaluating rate of refusal to participate
Aikaikkuna: At end of enrollment (Up to 1 year)
|
Number of participants refusing to consent.
|
At end of enrollment (Up to 1 year)
|
|
Feasibility as assessed by rate of attrition
Aikaikkuna: At 8 weeks post end of enrollment (Up to 1 year)
|
Number of participants dropping out after start of intervention for any reason.
|
At 8 weeks post end of enrollment (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Aikaikkuna: At 8 weeks after study start (Up to 1 year)
|
Number of times participant practices during study, documented via website data capture
|
At 8 weeks after study start (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Aikaikkuna: At 8 weeks after study start (Up to 1 year)
|
Number of times participant watches recorded webinars, documented via website data capture
|
At 8 weeks after study start (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Aikaikkuna: At 8 weeks after study start (Up to 1 year)
|
Number of times patient participates in live webinars, documented via roll-call.
|
At 8 weeks after study start (Up to 1 year)
|
|
Acceptability as assessed by adherence to practice instructions
Aikaikkuna: At 8 weeks after study start (Up to 1 year)
|
Average duration of meditation session (measured in minutes), documented via website data capture.
|
At 8 weeks after study start (Up to 1 year)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Efficacy as assessed by National Comprehensive Cancer Network (NCCN) Distress Thermometer
Aikaikkuna: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
0 to 10, with 10 being the worst level of distress
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
|
Efficacy as assessed by National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH PROMIS)
Aikaikkuna: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
|
|
Efficacy as assessed by a Five Facet Mindfulness Questionnaire Short (FFMQ-SF)
Aikaikkuna: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
|
|
Efficacy as assessed by a "Are You at Peace?" one-item spiritual probe
Aikaikkuna: At baseline, week 4 and week 8 after study start (Up to 1 year)
|
At baseline, week 4 and week 8 after study start (Up to 1 year)
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Chloe Atreya, MD, University of California, San Francisco
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 174534 (Integrated Research Application System)
- NCI-2018-00622 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .